Stock Analysis
- Japan
- /
- Personal Products
- /
- TSE:4925
HABA LaboratoriesInc Full Year 2024 Earnings: JP¥560 loss per share (vs JP¥187 loss in FY 2023)
HABA LaboratoriesInc (TSE:4925) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥12.3b (up 2.4% from FY 2023).
- Net loss: JP¥2.12b (loss widened by 200% from FY 2023).
- JP¥560 loss per share (further deteriorated from JP¥187 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
HABA LaboratoriesInc shares are down 1.2% from a week ago.
Risk Analysis
You still need to take note of risks, for example - HABA LaboratoriesInc has 3 warning signs (and 2 which don't sit too well with us) we think you should know about.
Valuation is complex, but we're here to simplify it.
Discover if HABA LaboratoriesInc might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About TSE:4925
HABA LaboratoriesInc
Manufactures and sells skin care, and hair and body care products in Japan and internationally.